Structure Therapeutics (NASDAQ:GPCR) Trading 5.3% Higher - Still a Buy?

Key Points

• Structure Therapeutics (NASDAQ: GPCR) saw its stock increase by 5.3%, trading at $21.14 after previously closing at $20.08, but the trading volume was down 82% compared to its average.
• Wall Street analysts have rated Structure Therapeutics with a consensus "Buy" rating and a target price averaging $75.71, despite recent adjustments from several firms.
• The company reported a quarterly loss of ($0.36) earnings per share, missing estimates, and analysts expect a total loss of -0.82 earnings per share for the fiscal year.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) was up 5.3% on Wednesday . The company traded as high as $21.08 and last traded at $21.14. Approximately 151,624 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 854,934 shares. The stock had previously closed at $20.08.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GPCR shares. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. JMP Securities lowered their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Guggenheim reduced their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Trading Down 0.2%

The company's 50-day simple moving average is $18.91 and its 200-day simple moving average is $20.77. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -19.00 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in GPCR. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics during the 4th quarter valued at approximately $34,000. State of Wyoming bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $28,000. Assetmark Inc. increased its position in shares of Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after buying an additional 820 shares during the period. National Bank of Canada FI raised its stake in Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after buying an additional 2,766 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.